254 related articles for article (PubMed ID: 19509364)
1. New trial data do not end the PSA screening debate.
Vastag B
J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
[No Abstract] [Full Text] [Related]
2. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
3. Localized prostate cancer: quality of life meets Whitmore's legacy.
Bermejo C; Kristal AR; Zeliadt SB; Ramsey S; Thompson IM
J Natl Cancer Inst; 2004 Sep; 96(18):1348-9. PubMed ID: 15367562
[No Abstract] [Full Text] [Related]
4. Clinical practice. Screening for prostate cancer.
Hoffman RM
N Engl J Med; 2011 Nov; 365(21):2013-9. PubMed ID: 22029754
[No Abstract] [Full Text] [Related]
5. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
6. The prostate cancer conundrum.
Albertsen PC
J Natl Cancer Inst; 2003 Jul; 95(13):930-1. PubMed ID: 12837821
[No Abstract] [Full Text] [Related]
7. Does the benefit justify the risk?
Albertsen PC
J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059
[No Abstract] [Full Text] [Related]
8. Prostate specific antigen and screening for early prostate cancer.
Davidson P
N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
[No Abstract] [Full Text] [Related]
9. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
10. Should men over the age of 65 years receive PSA screening? Argument against.
Albertsen PC
Nat Clin Pract Urol; 2008 May; 5(5):232-3. PubMed ID: 18349860
[No Abstract] [Full Text] [Related]
11. Lung cancer screening gets risk-specific.
Peres J
J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
[No Abstract] [Full Text] [Related]
12. An argument against routine prostate cancer screening.
Hoffman RM
Arch Intern Med; 2003 Mar; 163(6):663-5; discussion 665-6. PubMed ID: 12639196
[No Abstract] [Full Text] [Related]
13. Is screening for prostate cancer the current gold standard?--"no".
Kramer BS; Gohagan JK; Prorok PC
Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515
[No Abstract] [Full Text] [Related]
14. Prostate specific antigen screening.
Block KI
Integr Cancer Ther; 2009 Jun; 8(2):111-2. PubMed ID: 19679618
[No Abstract] [Full Text] [Related]
15. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
16. What to do with an abnormal PSA test.
Loeb S; Catalona WJ
Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
[TBL] [Abstract][Full Text] [Related]
17. Is an improved PSA screening test in sight?
Savage L
J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
[No Abstract] [Full Text] [Related]
18. Prostate-specific antigen testing. Should we recommend it?
Hickey J
Can Fam Physician; 2003 Mar; 49():303-4. PubMed ID: 12675542
[No Abstract] [Full Text] [Related]
19. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
20. One man at a time--resolving the PSA controversy.
McNaughton-Collins MF; Barry MJ
N Engl J Med; 2011 Nov; 365(21):1951-3. PubMed ID: 22029758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
